false 0001091596 0001091596 2022-12-02 2022-12-02
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): December 2, 2022
 
Nuo Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
 
 
Delaware
000-28443
23-3011702
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
 
8285 El Rio, Suite 190, Houston, Texas 77054
(Address of principal executive offices) (Zip Code)
 
(346) 396-4770
(Registrant’s telephone number, including area code)
 
Not applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
 
Securities registered pursuant to Section 12(b) of the Act:  None
 
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 
 
 
Item 5.07 Submission of Matters to a Vote of Security Holders.
 
On December 2, 2022, Nuo Therapeutics, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders. The following matters were considered and voted upon:
 
 
1.
To elect four directors to serve on the Company’s Board of Directors, each to serve until the Company’s next annual meeting of stockholders or until each successor is duly elected and qualified;
 
 
2.
To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
 
 
3.
To approve, on an advisory basis, the compensation of the Company’s named executive officers;
 
 
4.
To approve, on an advisory basis, the frequency of the advisory vote on executive compensation; and
 
 
5.
To ratify and approve the Company’s 2016 Omnibus Incentive Compensation Plan, as amended.
 
The results of the vote were as follows:
 
 
1.
Election of Directors
For
Withheld
Broker Non-Votes
  
 
David E. Jorden
26,699,444
3,323
996,251
  
 
C. Eric Winzer
26,198,490
504,277
996,251
  
 
Scott M. Pittman
26,199,444
503,323
996,251
  
 
Paul D. Mintz
26,199,444
503,323
996,251
  
           
   
For
Withheld
Abstain
  
2.
To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022
27,697,944
1,074
0
  
   
For
Withheld
Abstain
  
3.
To approve, on an advisory basis, the compensation of the Company’s named executive officers
26,692,397
5,370
5,000
  
           
   
One Year
Two Years
Three Years
Abstain
4.
To approve, on an advisory basis, the frequency of the advisory vote on executive compensation
2,389,764
37,874
23,767,794
507,335
           
   
For
Withheld
Abstain
  
5.
To ratify and approve the Company’s 2016 Omnibus Incentive Compensation Plan, as amended
26,188,825
7,988
505,954
  
 
 
In light of the voting results on Proposal 4 the Board of Directors has determined that the Company will include an advisory vote on executive compensation in the Company’s proxy materials every three years until the next required advisory vote on the frequency of future advisory votes on executive compensation, which will occur no later than the Company’s 2028 Annual Meeting of Stockholders.
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Nuo Therapeutics, Inc.
  
       
       
 
By:  
/s/ David E. Jorden
  
   
David E. Jorden
  
   
Chief Executive and Chief Financial Officer
  
 
Date: December 5, 2022